Barclays initiated coverage of Align Technology (ALGN) with an Equal Weight rating and $170 price target The firm started the U.S healthcare technology and distribution industry with a neutral view. Barclays is most bullish on the drug distributors and has a more mixed view of the dental and healthcare information technology sub-sectors.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALGN:
- Angelalign price hike strengthens case for Align losing less share, says Stifel
- Align Technology announces commercial availability of Invisalign in Philippines
- Align Technology’s Earnings Call Highlights Growth Amid Challenges
- Early notable gainers among liquid option names on October 30th
- Align Technology price target raised to $170 from $160 at Evercore ISI